Corcept Therapeutics Incorporated (CORT) has agreed to sell 11.0 million common shares in an underwritten public offering of common stock. The company has also granted the underwriter a 30-day option to buy from it up to an additional 1.65 million shares.
Corcept plans to use the net proceeds from the offering to fund research and development activities, including clinical trials, and working capital and for general corporate purposes.
Credit Suisse Securities (USA) LLC is acting as sole book-running manager and underwriter in the offering.
For comments and feedback: editorial@rttnews.com